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Jong Hoo Lee1 and Su Wan Kim2*Abstract
Although diffuse alveolar hemorrhage complicating warfarin therapy is rare, it generally has a worsening clinical
course and can be a life threatening condition. A 56-year-old male who had undergone a pulmonary lobectomy for
lung cancer 2 years before had received warfarin for about 5 months due to pulmonary vein thrombosis. The
patient presented with severe dyspnea and had prolonged anticoagulation values. Chest X-ray and computed
tomography revealed diffuse pulmonary consolidations, and bronchoalveolar lavage demonstrated diffuse alveolar
hemorrhage. The reversal of anticoagulation was initiated, and extracorporeal membrane oxygenation was
performed for refractory respiratory failure that did not improve despite maximal mechanical ventilatory support.
The diffuse alveolar infiltrations resolved after 5 days, and we successfully weaned off both extracorporeal
membrane oxygenation and mechanical ventilation. Herein we report the detailed course of a case that was
successfully treated with extracorporeal membrane oxygenation as a bridge-to-recovery for warfarin- exacerbated
diffuse alveolar hemorrhage.
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Diffuse alveolar hemorrhage (DAH) refers to a clinical
syndrome, resulting from extensive bleeding in the acinar
portion of the lung [1]. It often presents with clinical
features of hemoptysis, anemia, diffuse radiographic alveo-
lar consolidation, and acute respiratory failure [1]. It is
caused by diseases that damage the alveolar capillary bar-
rier or by disorders of coagulation. These underlying
diseases include: lung infections, pulmonary embolism,
Wegener’s granulomatosis, Goodpasture’s syndrome, sys-
temic lupus erythematosus and Behçet’s syndrome [2].
Only a few reports have mentioned the manifestation of
alveolar hemorrhage in patients receiving anticoagulants,
such as warfarin and heparin [3]. Furthermore, DAH com-
plicating warfarin therapy is associated with a high mortal-
ity rate [4].* Correspondence: 95swan@hanmail.net
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reproduction in any medium, provided the orExtracorporeal membrane oxygenation (ECMO) can
be considered in patients with life-threatening acute re-
spiratory failure, such as severe hypoxemia, uncompen-
sated hypercapnia and the occurrence of excessively high
end-inspiratory plateau pressures, despite adequate man-
agement with a mechanical ventilator [5]. However, to
our knowledge, ECMO applied to patients with fatal
DAH has not been reported in the literature.
We report a case of successful application of ECMO
as a bridge-to-recovery therapy in a patient with fatal
warfarin-exacerbated diffuse alveolar hemorrhage.Case presentation
A 56-year-old male was admitted to our hospital with
aggravated dyspnea over the previous 24 hours. He had
a past medical history of right upper lobectomy for lung
adenocarcinoma two years before. The pathologic stage
was T3N1Mo (TNM stage IIIA), and adjuvant chemo-
therapy with vinca alkaloid (vinorelbine) had been
followed postoperatively. However, newly-developed
brain metastasis and metastatic nodules in the superiorLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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months after the lung resection. He had undergone a
whole brain radiation therapy and concurrent palli-
ative chemotherapy with variable sequential regimens
(pemetrexed, erlotinib, gemcitabine/cisplatin, and doce-
taxel) till six months before the re-admission. During
the subsequent follow up the patient had shown a stable
clinical course.
The patient was incidentally detected with right super-
ior pulmonary vein thrombosis on follow up chest
computed tomography, five months before the re-
admission, and complained intermittent right arm
swelling at this time. For the pulmonary vein throm-
bosis, he had been taking 2.0 mg to 2.5 mg of warfarin
for five months. Prothrombin times (International
Normalized Ratio, INR) had been usually controlled
within 1.8 to 3.3 (INR target range: around 2.0), and he
had not been prescribed other drugs that affect vitamin
K metabolism during the previous six months. At the
initial physical examination, the patient was looking very
acutely-ill and markedly dyspneic. He did not present
other respiratory symptoms like cough and hemoptysis.
His vital signs were as follows: blood pressure 130/80
mmHg, pulse rate 115 beats/min, respiratory rate 40/
min and body temperature 36.1°C. Auscultation revealed
diffuse inspiratory crackles over both lungs. Results of
laboratory investigations are shown in Table 1. There
was no evidence of renal or hepatic dysfunction or auto-
immune diseases. Any infection, heart failure, and plate-
let dysfunction were not suspect from the laboratory
findings.Table 1 Results of the initial laboratory investigations
Variables Results
Complete blood count test Chemistry
White blood cell 11,800/ul Creatinine
Hemoglobin 11.4 g/dL Potassium
Platelet count 226,000/ul Creatine p
Alanine tra
Arterial blood gas analysis Cardiac sp
pH 7.36
PaO2 51.5 mmHg Troponin-
PaCO2 34.0 mmHg CK-MB iso
SaO2 84.2 % N-termina
Coagulation panel Autoimm
aPTT 56 sec Proteinase
PT (INR) 86.3 sec (6.93) Anti-nucle
C-reactive protein 9.47 mg/dL Myelopero
Procalcitonin 0.26 mg/dL
ANCA, anti-neutrophil cytoplasmic antibody; aPTT, activated partial thromboplastinA chest X-ray revealed increased bilateral pulmonary
infiltrations, and chest computed tomography showed
newly developed extensive ground-glass attenuations with
crazy-paving appearance on whole lung fields (Figure 1).
Ceftriaxone (2.0 g, once daily) and levofloxacin (750 mg,
once daily) were empirically administered to prevent
pneumonia. Warfarin was discontinued, and 10 mg vita-
min K and 10 fresh frozen plasmas were administered
intravenously. The deranged INR and activated partial
thromboplastin time (aPTT) were corrected to 1.43 and
33 seconds respectively on the following day.
Since the patient’s oxygenation was not improved, des-
pite maximum oxygen therapy through facial mask,
endotracheal intubation and mechanical ventilation had
to be started. Bloody secretions through the endo-
tracheal tube were observed, and a flexible bronchos-
copy was performed. Fresh blood on the whole
bronchial system was observed, without any other
endobronchial lesions (Figure 2). The bronchoscope was
wedged into sub-segmental bronchi, and we confirmed
the diagnosis of DAH by finding bronchoalveolar lavage
(BAL) to become progressively more hemorrhagic. A
cytopathological analysis with iron stains was not
performed in the bronchoalveolar lavage (BAL) fluid. All
cultures of sputum, BAL fluid and blood did not reveal
any causative pathogens. The patient showed pure DAH
confined to the lungs, and there was no evidence of
disseminated intravascular coagulation or hemorrhagic
events occurring elsewhere in the body.
In spite of maximal ventilatory supports (pressure con-













xidase anti-neutrophil Cytoplasmic autoantibody Negative
time; BNP, B-type natriuretic peptide; CK, creatine phosphokinase.
Figure 1 Images at the time of admission. Chest X-ray (A) and computed tomography (B) reveal bilateral pulmonary infiltrations and extensive
ground-glass attenuations with crazy-paving appearance on whole lung fields.
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the patient remained severely hypoxemic (pH 7.36,
PaCO2 42.3 mmHg, PaO2 48.4 mmHg and SaO2 79.3%).
Since the patient had very small safety margin in the
remaining lung parenchyma, we decided to perform
ECMO, instead of prone position, nitric oxide inhalation,
and recruit maneuver.
A veno-venous type ECMO (EBS, CapioxW Emergency
Bypass System, Terumo Inc., Tokyo, Japan) was applied to
the patient on the day of hospitalization, with a 21-Fr
drainage cannula from the left femoral vein and a 17-Fr
return cannula into the right internal jugular vein
(Figure 3A). ECMO was instituted without heparinization
due to risk of alveolar hemorrhage. During ECMO, INR
and aPTT of the patient were maintained within 1.25 to
1.43 and 21 to 33 seconds, respectively. Mechanical venti-
latory care was minimally maintained (pressure control
mode, a pressure support of 10 mmHg, at a rate of 10
breaths/min, a positive end-expiratory pressure of 10
cmH2O, and a FiO2 of 0.3) for lung protective strategy.
Arterial blood gas analysis showed improved oxy-
genation and undisturbed gas exchange (Table 2), one
hour after the application of ECMO. On day 5 after
ECMO application, chest radiography showed diffuse pul-
monary infiltrations were resolving (Figure 3B), and theFigure 2 Bronchoscopic findings. Bronchoscopy shows fresh blood on woxygenation was improved, thus ECMO was removed.
The duration of ECMO was 126 hours, and there was no
complication associated with the procedure. An exchange
of the oxygenator membrane was not needed, even though
we did not use heparin. We performed extubation without
tracheostomy 3 days after ECMO removal. the patient was
discharged 42 days after the extubation and remained free
from respiratory symptoms. We did not prescribe warfarin
due to the concern of recurrent fatal DAH and the ab-
sence of symptoms of pulmonary or peripheral venous
thrombosis. The patient has been controlled recently and
is doing well.
Discussion
DAH is the result of the accumulation of intra-alveolar
red blood cells originating from the alveolar capillaries
[1]. Generally, DAH may develop in several pathologic
conditions, including various vasculitis, autoimmune
diseases, acute post-streptococcal glomerulonephritis, and
potentially any pneumorenal syndrome. Uncommonly,
drugs, such as inhaled cocaine, diphenyl-hydantoin,
sirolimus, leflunomide, and everolimus, can also lead to
DAH [6].
Warfarin (Coumadin) is a frequently prescribed oral
anticoagulant inhibiting vitamin K utilization by the liverhole bronchial system.
Figure 3 Conduction of extracorporeal membrane oxygenation (ECMO). Chest radiography shows diffuse pulmonary consolidations and a
return cannula into the right internal jugular vein for ECMO (A), and improved bilateral pulmonary infiltrations after removal of ECMO (B).
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tissue, including the brain, and gastrointestinal or
genitourinary tracts. However, the rate of alveolar
hemorrhage in patients taking anticoagulant therapy is
low and forms a minor part of bleeding complications
[7-9]. DAH is a rare complication of warfarin therapy.
DAH occurs rarely with high dose taken by children and
young adults for suicide [10]. Since the first case of DAH
caused by warfarin intoxication reported by Brown et al.
[11] in 1965, few other reports have been described in the
literature [12]. Warfarin-induced DAH is usually severe
and can be lethal [4]. In the future, the incidence of
anticoagulants-induced DAH may increase because of the
growth of elderly population, who need anticoagulants
due to conditions, such as atrial fibrillation, cardiovascular
diseases, and valvular heart diseases. Furthermore, the
new anticoagulants, such as abciximab and epifibatide, are
more potent, and DAH induced by these drugs has re-
cently been recently reported [13,14].
Our patient had abruptly increased INR, PT and aPTT.
Although we investigated other concomitant drugs,Table 2 Changes in respiratory, ECMO, and coagulation varia
Variables Before ECMO 1 hour after ECMO 12
pH 7.36 7.49
PaCO2 (mmHg) 42.3 27.8
PaO2 (mmHg) 48.4 59.0
SaO2 (%) 79.3 91.4
FiO2 in ECMO (%) - 100
Blood flow in ECMO (L/min) - 4.0
Tidal volume (ml) 240 200
Peak inspiratory pressure (cmH2O) 34 20
PEEP (cmH2O) 14 10
FiO2 in ventilator (%) 100 30
aPTT (sec) 56 -
PT (INR) 6.93 -
ECMO, Extracorporeal membrane oxygenation.trauma, or infections, we could not find the etiology of
the suddenly prolonged anticoagulation. We did not
examine the genetic polymorphisms of cytochrome P-
450 enzyme 2C9 (CYP2C9) and vitamin K epoxide re-
ductase complex 1 (VKORC1), which can affect the
management of warfarin therapy. CYP2C9 is a key en-
zyme in the hepatic metabolism of warfarin. On the
other hand, VKORC1 has a role in maintaining sufficient
vitamin K levels when dietary vitamin K is limited, and
the VKORC1 homozygous mutation affects the high re-
sponse to warfarin [15].
We would highlight two points from this case. Firstly, it
is very important to confirm an early diagnosis in clinically
suspected patients with DAH, because it can be lethal due
to anemia and respiratory failure. BAL is the gold standard
for the diagnosis, and progressively hemorrhagic BAL
finding in serial samples or positive iron studies of BAL
will confirm the diagnosis [1]. However, a careful ap-
proach is needed because bronchoscopy itself can cause
massive pulmonary bleeding. Secondly, as DAH compli-
cating warfarin therapy is associated with a high mortalitybles
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the treatment was reversal of the anticoagulation. It is life-
saving to reverse anticoagulation by giving vitamin K and
fresh frozen plasma early. The other principle of treatment
is to maintain the patient’s oxygenation through aggressive
treatment, via mechanical ventilation or ECMO when
needed. We decided to start ECMO as a bridge-to-recovery
or rescue therapy to maintain oxygenation, and ECMO
was instrumental in saving patient’s life. To our know-
ledge, there are no previous reports of ECMO applied to
patients with warfarin-induced DAH.
ECMO is an extracorporeal circuit that directly
oxygenates the red blood cells and removes carbon dio-
xide from the blood. In patients with respiratory failure,
while the results of the previous clinical trials did not
show any survival benefit using ECMO or extracorporeal
carbon dioxide removal [16,17], the recent CESAR study
(Conventional Ventilation or ECMO for Severe Adult
Respiratory Failure) using modern ECMO technology
reported favorable outcomes [18]. Nowadays, ECMO is
considered a bridge-to-recovery therapy in patients with
profound gas-exchange abnormalities despite mechanical
ventilation. As results of clinical studies and experiences
were accumulating the indications for ECMO application
have been increased.
During ECMO, there is continuous contact between the
circulating blood and the foreign surface of the circuit [19].
The hemostatic balance is shifted to hypercoagulability with
patients and extracorporeal circuits and components at risk
for thrombosis. In order to regain the loss of hemostatic
balance and prevent thrombosis, administration of
antithrombotic drug, such as heparin, is necessary [20]. Un-
fortunately, the use of heparin can result in bleeding in the
systemic circulation and despite its use, clotting in the
extracorporeal circuit. The bleeding and thrombosis that
occur regularly during the course of ECMO can ultimately
result in significant clinical complications. Surgical site
bleeding, the most common source of bleeding, is reported
in 6-32% of ECMO patients with the highest incidence oc-
curring in patients who have had recent cardiac surgery
[21]. Intracranial hemorrhage, the most potentially devas-
tating bleeding complication occurs in 3-6% of patients.
Hypoxemia, acidosis, and cardiovascular instability prior to
initiation of ECMO, and coagulopathy all increase the risk
for intracranial hemorrhage [22]. Many unanswered
questions exist concerning therapies to maintain the
hemostatic balance during ECMO, including the optimal
combination, duration and dosage of antithrombotic agents
needed to limit bleeding and thrombotic complications.
Our practice is to use venovenous type ECMO for adult
patients with respiratory failure. An echocardiogram prior
to ECMO should be performed to confirm ventricular
function is preserved. Heparin is infused to maintain an
activated clotting time (ACT) of 140–160 seconds forvenovenous ECMO and 180–210 seconds for venoarterial
ECMO. We do not use any anticoagulants with our patient
because heparin should promote the alveolar hemorrhage,
and the thrombotic complications would be less serious
venovenous ECMO than in venoarterial ECMO. Other-
wise, venovenous ECMO can lead to significant alveolar
hemorrhage or worsening of pre-existing alveolar
hemorrhage. This could be related to ECMO flow directly
into the right heart and pulmonary artery with shear forces
disrupting the capillary bed, and observed by pulmonary
arterial cannulation. If hypoxemia could not be improved
and right heart failure aggravated despite venovenous
ECMO, additional cannulation for venous drainage should
be performed or conversion to venoarterial ECMO should
be mandatory.
In practice, patients undergoing ECMO generally are
subjected to early tracheostomy because of the need for
prolonged management of underlying lung diseases.
However, we did not perform tracheostomy, considering
the high reversibility of DAH, and the patient had a fa-
vorable outcome. In patients with ECMO, tracheostomy
should be selectively performed after considering the
rapid reversibility of the underlying lung disease.
Conclusions
Although warfarin-exacerbated DAH is rare, it can lead
to potentially fatal respiratory failure. If a patient with
warfarinization shows over-anticoagulation, prompt diagno-
sis and aggressive treatment for DAH should be performed
considering a possible warfarin-exacerbated hemorrhage.
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